Drugs / SB-751689
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT00532077 | Aug 2007 → Jan 2008 | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00508534 | Jul → Aug 2007 | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00540878 | Apr 2007 → ? | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00468689 | Apr → Aug 2007 | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00499928 | Apr → Jul 2007 | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00554255 | Oct → Dec 2006 | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00388596 | Oct 2006 → ? | osteoporosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00548496 | Sep 2007 → Nov 2008 | — | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-751689 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00388596 ↗ |
| Action | Inhibit | “[14C]-SB-751689 (a Calcium-Sensing Receptor Antagonist)” NCT00499928 ↗ |
| Route | Oral | “SB-751689 oral tablets (100 and 400 ng)” NCT00468689 ↗ |
| Target | CASR | “ronacaleret, a novel calcium-sensing receptor antagonist” PMID 21742071 ↗ Jun 2011 |